Oasmia Pharmaceutical, which is developing formulations of widely-used cancer drugs for humans and dogs, narrowed the range and added a co-manager for its IPO on Tuesday.
The Uppsala, Sweden-based company plans to raise up to $23 million by offering ADSs at a price range of $5.75 to $7.75. The company will command a market cap of approximately $200 million after the offering, based on current trading on Nasdaq Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX).
Oasmia Pharmaceutical, which was founded in 1999, plans to list on the Nasdaq under the symbol OASM. Oasmia Pharmaceutical initially filed confidentially on 5/30/2014. Ladenburg Thalmann & Co. is the sole bookrunner on the deal. It is expected to price next week.
